Chronic Lymphocytic Leukemia (CLL)
Conditions
Brief summary
To evaluate the effectiveness and safety of forodesine in CLL patients
Detailed description
To investigate the efficacy (complete response \[CR\] + partial response \[PR\]) of forodesine in treating subjects with CLL who have failed at least one prior treatment regimen or who are treatment naïve but are either elderly, have poor performance status or are otherwise predicted not to tolerate cytotoxic chemotherapy.
Interventions
DRUGforodesine HCl
2 x 100mg capsules daily
Sponsors
BioCryst Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years and older 2. Diagnosis of CLL established by peripheral blood and/or bone marrow examination and using the standard diagnostic criteria. 3. Subjects with Rai stage III or IV, or earlier stage requiring therapy as determined by the 1996 National Cancer Institute -Working Group (NCI-WG) criterion 4. Primary resistant (no CR or PR) or progressive disease after response to at least one prior treatment regimen OR treatment naïve subjects who meet at least one of the following criteria. 1. age \>65 years 2. Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4 3. Inability to tolerate standard cytotoxic chemotherapy in the opinion of the treating physician. 5. ECOG performance status of 0, 1, or 2 (for subjects with primary resistance or progressive disease after response to at least one prior treatment regimen). 6. Willing to take adequate contraceptive measures (i.e., latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration of the study and 3 months after, except for patients who are post menopausal or have prior hysterectomy. 7. All investigational treatments should have been discontinued for at least 3 weeks prior to the initiation of the study drug.
Exclusion criteria
1. Pregnant or nursing. 2. Unable or unwilling to sign consent. 3. Severe, ongoing co-morbid conditions, which would preclude safe delivery of the investigational therapy. 4. Active serious infections that are not controlled by antibiotics. 5. ECOG performance status \>2 (except for treatment naïve subjects where ECOG performance status 0, 1 or 5 is excluded). 6. Inadequate renal function: creatinine \> or equal to 2.0 unless related to the disease. 7. Inadequate liver function: bilirubin \> or equal to 3.0; transaminases \> or equal to 3.0 times the upper limit of normal unless related to the disease. 8. Known positive test for human immunodeficiency virus (HIV). 9. Subjects with known hepatitis B and/or hepatitis C active infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate | Up to 6 cycles of therapy |
Countries
Australia, United States
Outcome results
None listed